Advanced Equipment Manufacturing

In 2025, Fujian Province had 4,975 above-designated-size machinery and equipment enterprises. The year-on-year growth in industrial value-added was 12.9%, achieving an operating revenue of RMB 1,251.44 billion, a year-on-year increase of 7.7%. The advanced equipment manufacturing cluster possesses a number of advantageous specialty products and industries. It is a national hub for major engineering machinery manufacturing, large and medium-sized bus manufacturing, large commercial aircraft maintenance, shipbuilding and repair, and small and medium-sized motor manufacturing. Fujian's electric vessel sector, with advantages such as a complete industry chain, core equipment market share exceeding 40%, and a leading number of built and under-construction certified electric vessels nationwide, has established multi-dimensional leadership in policy, technology, and application scenarios. Fujian is a pioneering province for the green and intelligent development of coastal and inland vessels in China. Leading enterprises include Southeast Chery, SAIC Motor (Ningde), Xiamen King Long, Fujian Shipbuilding Industry Group, and Fujian Mercedes-Benz.

Biomedicine

In 2025, Fujian Province had 341 above-designated-size pharmaceutical enterprises, achieving an operating revenue of RMB 50.28 billion. The province's pharmaceutical industry has cultivated a relatively comprehensive industrial system covering categories such as chemical APIs (active pharmaceutical ingredients), chemical drug preparations, biopharmaceuticals, traditional Chinese medicine (TCM) prepared prescriptions, TCM decoction pieces, and medical devices. During the "14th Five-Year Plan" period, 4 Category-1 innovative drugs and 4 Category-2 innovative drugs were approved, accelerating industrial innovation. Maxim Biotech and Double Medical were promoted as leaders in the industrial chain. 6 projects from 3 enterprises, including Double Medical, were shortlisted for the Ministry of Industry and Information Technology's List of “Open Bidding for Selecting the Best Candidates for Innovation Tasks in Biomedical Materials.” 11 provincial-level industrial leading enterprises in biomedicine, such as Zhangzhou Pien Tze Huang Pharmaceuticals, and 17 enterprises under cultivation for leading status were fostered. 3 enterprises, including AmoyDx, were recognized as national single-item champions (in specific products); 25 enterprises, including Fukang Pharmaceuticals, were recognized as provincial single-item champions (in specific products). 19 pharmaceutical enterprises, including Southern Pharmaceuticals and Fukang Pharmaceuticals, were recognized as National "Little Giants" Enterprises Using Specialized and Advanced Technologies to Create Innovative and Unique Products. 15 enterprises, including Double Medical, Cosunter Pharmaceutical, and Haixi Pharmaceuticals, are listed companies.